Synthesis and evaluation of substituted 4-aryloxy- and 4-arylsulfanyl- phenyl-2-aminothiazoles as inhibitors of human breast cancer cell proliferation

Bioorganic and Medicinal Chemistry

Volumn 12, Issue 5, 2004, Pages 1029-1036

  Gorczynski, Michael J ^a   Leal, Rachel M ^b   Mooberry, Susan L ^b   Bushweller, John H ^a   Brown, Milton L ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b SW Foundation of Biomedical Research ^*  (United States)

Author keywords

2 Aminothiazoles; Breast cancer; Diaryl ethers; Substituent effects

Indexed keywords

2 AMINOTHIAZOLE DERIVATIVE; 4 (4' PHENOXYPHENYL)THIAZOL 2 YLAMMONIUM IODIDE; 4 (4' PHENYLSULFANYLPHENYL)THIAZOL 2 YLAMMONIUM IODIDE; 4 [4 (2' CHLOROPHENOXY)PHENYL]THIAZOL 2 YLAMMONIUM IODIDE; 4 [4 (3' CHLOROPHENOXY)PHENYL]THIAZOL 2 YLAMMONIUM IODIDE; 4 [4 (3' ETHOXYCARBONYLPHENOXY)PHENYL]THIAZOL 2 YLAMMONIUM IODIDE; 4 [4 (3',4' DICHLOROPHENYLSULFANYL)PHENYL]THIAZOL 2 YLAMMONIUM IODIDE; 4 [4 (4' CHLOROPHENYLSULFANYL)PHENYL]THIAZOL 2 YLAMMONIUM IODIDE; 4 [4 (4' METHOXYPHENYLSULFANYL)PHENYL]THIAZOL 2 YLAMMONIUM IODIDE; 4 [4' (3,4 DICHLOROPHENOXY)PHENYL]THIAZOL 2 YLAMMONIUM IODIDE; 4 [4' (4 CHLOROPHENOXY)PHENYL]THIAZOL 2 YLAMMONIUM IODIDE; 4 [4' (4 METHOXYPHENOXY)PHENYL]THIAZOL 2 YLAMMONIUM IODIDE; 4 [4' (4 PHENOXYPHENOXY)PHENYL]THIAZOL 2 YLAMMONIUM IODIDE; 4 [4' (4 TOLUOXY)PHENYL]THIAZOL 2 YLAMMONIUM IODIDE; 4 [4' (4 TOLYLSULFANYLPHENYL)]THIAZOL 2 YLAMMONIUM IODIDE; 4 [4' (BIPHENYL 4 YLOXY)PHENYL]THIAZOL 2 YLAMMONIUM IODIDE; ANTINEOPLASTIC AGENT; DOXORUBICIN; ESTROGEN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN CELL;

ANIMALIA;

EID: 1342300674     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2003.12.003     Document Type: Article

References (24)

1. Ries, L. A. G.; Eisner, M. P.; Kosary, C. L.; Hankey, B. F.; Miller, B. A.; Clegg, L.; Mariotto, A.; Fay, M. P.; Feuer, E. J.; Edwards, B. K. (Eds), SEER Cancer Statistics Review, 1973-2000, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2000 , 2003.
2. Alloatti G., Penna C., Gallo M.P., Levi R.C., Bombardelli E., Appendino G. J. Pharmacol. Exp. Ther. 284:1998;561.
3. Hortobagyi G.N., Buzdar A.U. Drugs. 45(Suppl. 2):1993;10.
4. Kaklaman V.G., Gradishar W.J. Clin. Breast Cancer. 4(Suppl. 1):2003;S26.
5. Chlebowski R.T., Col N., Winer E.P., Collyar D.E., Cummings S.R., Vogel V.G. III, Burstein H.J., Eisen A., Lipkus I., Pfister D.G. J. Clin. Oncol. 20(15):2002;3328.
6. Bilodeau, M. T.; Manley, P. J.; Hartman, G. D. U.S. Patent 6,586,424, 2003.
7. Bilodeau, M. T.; Hartman, G. D. US Pat. Appl. 20030100567, 2003.
8. Bilodeau, M. T.; Hartman, G. D.; Hoffman, J. M.; Lumma, W. C., Jr.; Manley, P. J.; Rodman, L.; Sisko, J. T.; Smith, A. M.; Tucker, T. J. US Pat. Appl. 20020137755, 2002.
9. Kim K.S., Kimball S.D., Misra R.N., Rawlins D.B., Hunt J.T., Xiao H., Lu S., Qian L., Han W., Shan W., Mitt T., Cai Z., Poss M.A., Zhu H., Sack J.S., Tokarski J.S., Chang C.Y., Pavletich N., Kamath A., Humphreys W.G., Marathe P., Bursuker I., Kellar O.K.A., Roongta U., Batorsky R., Mulheron J.G., Bol D., Fairchild C.R., Lee F.Y., Webster K.R. J. Med. Chem. 45(18):2002;3905.
10. Wilson K.J., Illig C.R., Subasinghe N., Hoffman J.B., Rudolph M.J., Soll R., Molloy C.J., Bone R., Green D., Randall T., Zhang M., Lewandowski F.A., Zhou Z., Sharp C., Maguire D., Grasberger B., DesJarlais R.L., Spurlino J. Bioorg. Med. Chem. Lett. 11(7):2001;915.
11. Tuse, D., Chen, X., Laderoute, K. R., Hiebert, C. K., Olsen, C. M. U.S. Patent 6,169,104, 2001.
12. Yeager G.W., Schissel D.N. Synthesis. 1:1991;63.
13. Chordia M.D., Murphree L.J., Macdonald T.L., Linden J., Olsson R.A. Bioorg. Med. Chem. Lett. 12(12):2002;1563.
14. Monks A., Scudiero D., Skehan P., Shoemaker R., Paull K., Vistica D., Hose C., Langley J., Cronise P., Vaigro-Wolff A. J. Natl, Cancer Inst. 83:1991;757.
15. Gray G.D., Wickstrom E. Biotechniques. 21(5):1996;780.
16. Tinley T.L., Randall-Hlubek D.A., Leal R.M., Jackson E.M., Cessac J.W., Quada J.C. Jr., Hemscheidt T.K., Mooberry S.L. Cancer Res. 63:2003;3211.
17. Kimoto S., Asaki K., Kishi S. J. Pharm. Soc. Japan. 74:1954;358. Chem. Abs. 1955, 5373.
18. Markley L.D., Tong Y.C., Dulworth J.K., Steward D.L., Goralski C.T., Johnston H., Wood S.G., Vinogradoff A.P., Bargar T.M. J. Med. Chem. 29(3):1986;427.
19. Petit L., Buu-Hoï A. J. Org. Chem. 26:1961;3832.
20. Szmant H.H., Palopoli F.P. J. Am. Chem. Soc. 72:1950;1757.
21. Hargrave K.D., Hess F.K., Oliver J.T. J. Med. Chem. 26(8):1983;1158.
22. Kawamatsu Y., Sohda T., Imai Y. Eur. J. Med. Chem. Chim. Ther. 16(4):1981;355.
23. For additional details concerning this screen and the NCI's drug discovery and development program, visit http://dtp.nci.nih.gov/branches/btb/ ivclsp.html.
24. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J.T., Bokesch H., Kenney S., Boyd M.R. J. Natl. Cancer Ins. 82:1990;1107.